Canada markets closed

Filament Health Corp. (FLHLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.09000.0000 (0.00%)
At close: 03:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0900
Open0.1052
BidN/A x N/A
AskN/A x N/A
Day's Range0.0900 - 0.0900
52 Week Range0.0808 - 0.3680
Volume6,100
Avg. Volume5,757
Market Cap17.363M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
  • CNW Group

    FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS

    Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized dr

  • GlobeNewswire

    KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3OGHgD4 The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Comp

  • CNW Group

    FILAMENT HEALTH ANNOUNCES FOURTH PATENT ISSUANCE

    Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent was issued by the Canadian Intellectual Property Office (CIPO) and describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-g